Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Small cap pharmaceutical firm 4D Pharma posted a first half loss of £11.3m, unchanged year-on-year.
In terms of operational developments, the company commenced a Phase I/II study of MRx0518 in combination with Keytruda in collaboration with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA).
The two-part study is evaluating the safety, tolerability and preliminary clinical benefit of the combination in patients with melanoma, non-small-cell lung carcinoma (NSCLC), renal and bladder cancers who have relapsed on prior anti-PD-1 therapy.
Also there was the commencement of a Phase Ib study of MRx0518 as a monotherapy in the neoadjuvant setting. The two-part study will evaluate the safety, tolerability and anti-tumour immunological effects of MRx0518 in patients with multiple solid tumour types.
And 4D presented the first data on 4D's second-generation immuno-oncology candidate, MRx1299, outlining the mechanism of action and preliminary efficacy in preclinical models. Publication of the mechanism of action of MRx0518, outlining the bacterial effector molecule and host receptor which mediate its therapeutic effect.
Chairman David Norwood said: 'As our lead programmes progress towards generation of clinical data, the company continues to advance research in the field with the exciting developments in our neurodegeneration programmes.
'Alongside this we continue to strengthen the business corporately as we welcome the new members to the Board.'
At 8:54am: (LON:DDDD) 4d Pharma Plc Ord 0.25p share price was -1.5p at 98.5p